Cynata Enters Letter of Intent for Strategic Alliance in Japan...

Cynata Enters Letter of Intent for Strategic Alliance in Japan Melbourne, Australia and Tokyo, Japan; 3 December 2015: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has signed a Letter of Intent (LOI) regarding a future strategic alliance with Regience K.K. for Japan and certain other Asian countries. Cynata and Regience have identified a mutually beneficial business opportunity to enter a business partnership under which Regience would license, develop and commercialise Cynata’s proprietary Cymerus™ therapeutic mesenchymal stem cell (MSC) technology in certain territories, including Japan.

During the coming weeks, under the LOI, Regience and Cynata will evaluate and define a commercial relationship, and, if appropriate, enter a strategic alliance agreement. “We are very pleased to be considering a partnership with Cynata in the development and commercialisation of Cymerus, a very innovative therapeutic MSC technology. Japan is a key market for regenerative medicine and Cymerus represents a truly scalable manufacturing technology for therapeutic MSCs which will be essential in treating major diseases”, said President and Chief Executive Officer at Regience, Masanori Murayama. “We are very pleased to enter into the LOI with Regience, a company that we believe offers Cynata an outstanding opportunity to take our technology into one of the most dynamic and progressive markets for regenerative medicine,” said Dr Ross Macdonald, Chief Executive Officer and Managing Director at Cynata. “A champion of Japan’s global leadership role in regenerative medicine, Regience has very successfully driven unique opportunities for regenerative medicine based therapeutics in Japan, the world’s second largest country market for pharmaceutical products. Supported by several leaders in the biopharmaceutical space, Regience is building a very promising business in this field and we look forward to reviewing all options for Cymerus”.